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The Human Proteomics Organization (HUPO) Human Plasma Proteome Project (PPP) is a
prominent example of the inherently collaborative nature of the overall community effort to
characterize the proteome of humans in health and disease. The PPP Pilot Phase, called
“Exploring the Human Plasma Proteome”, engaged 55 laboratories, four technical committees,
and vendors and sponsors on an international scale. Among other outcomes, the PPP generated
a Core Dataset of 3020 proteins identified with two or more peptides, fully accessible at EBI/
PRIDE, ISB/PeptideAtlas, and University of Michigan websites, a rich resource for follow-on
analyses. The PPP provided extensive annotation, correlation of number of peptides with protein
concentrations measured by immunoassay, an algorithm for choice of a representative protein
for multiple proteins matching a given peptide, and independent analyses from the raw spectra.
The next phase of the PPP will emphasize standardized procedures for specimen handling,
potent new technology platforms for discovery and for targeted proteomics, and robust infor-
matics efforts, including comparative analyses of other biofluids.
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1 Introduction
The HUPO Plasma Proteome Project (PPP) was initiated in
2002. It is part of a broad array of HUPO initiatives ([1–3];
www.hupo.org). Through its initiatives, its annual World
Congress of Proteomics, the many active regional and
national HUPO organizations, relationships with leading
journals, and cooperation with EU and USA biomarker dis-
covery and proteomics technology development initiatives,
HUPO is having a major influence on acceleration of pro-
gress in proteomics.
The long-term scientific goals of the PPP are (i) compre-
hensive analysis of the protein constituents of human
plasma and serum; (ii) identification of biological sources of
variation within individuals over time due to physiology (age,
gender, menstrual cycle, exercise, stress, diet), pathology
(various diseases, special cohorts), and treatments (common
medications); and (iii) determination of the extent of varia-
tion across individuals within populations and across popu-
lations, due to genetic, nutritional, and other factors. The
purpose of this report is to review the goals, development,
and findings of the Pilot Phase of the PPP, to share some of
the challenges and lessons of this significant collaborative
effort, and to affirm the plans of HUPO to foster cross-anal-
yses of organ and biofluid proteomes with the plasma or
serum proteome.
The PPP Pilot Phase (Fig. 1) analyzed PPP reference
specimens of human serum and EDTA-, heparin-, and cit-
rate-anti-coagulated plasma; evaluated advantages and lim-
itations of many depletion, fractionation, and MS technology
platforms; and created a publicly available knowledge
base at www.ebi.ac.uk/pride; www.peptideatlas.org and
www.bioinformatics.med.umich.edu/hupo/ppp. Protocols
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Figure 1. Scheme showing aims and linkages of the HUPO
Plasma Proteome Project. Adapted from [2].
were developed by technical committees, and discussed and
adopted at an investigators’ workshop in July 2003. Many
potential reference specimens were considered, ranging
from aliquots of a pooled specimen from as many as 10 000
individuals (American Red Cross) to a single specimen from
one or a few individuals. We chose to prepare sets of serum
and plasma specimens from male-female donor pairs from
four different ethnicities, to begin to address interests of the
various investigators. The reference specimens were pre-
pared by BD and its contractor and were distributed globally,
beginning in September 2003. Each laboratory received
1.0 mL of the reference specimens requested. They used
their established and emerging technologies for fractiona-
tion and analysis of proteins. They were encouraged to “push
the limits” of their methods to detect and identify low abun-
dance proteins.
The PPP Pilot Phase was highly collaborative. Thirty-five
participating laboratories in 13 countries submitted datasets
to the Data Coordinating Center at the University of Michi-
gan. A small grants program facilitated follow-on analyses by
15 laboratories. An intensive 4-day Jamboree Workshop was
held in June 2004 for real-time cross-analyses and identifica-
tion of further analyses to be done. Working groups ad-
dressed specimen stability and protein concentrations; pro-
tein identifications from MS/MS datasets from 18 labora-
tories; independent analyses from the raw MS/MS spectra;
search engine performance, subproteome analyses, and bio-
logical insights; antibody arrays; and direct MS/SELDI anal-
yses across 10 laboratories. The 3020 proteins in the Core
Dataset were characterized with Gene Ontology, InterPro,
Novartis Atlas, OMIM, and immunoassay-based concentra-
tion determinations. The findings were reported in depth in
28 articles of a special issue of PROTEOMICS in August
2005 [4] and a Wiley book in 2006 [5].
As discussed in other articles in this issue, proteomic
analyses of plasma or serum must cope with the challenges
of high complexity, extreme dynamic range of concentra-
tions, physiological and genetic variation, and still-evolving
methods and databases for identification of peptides and
matching to protein sequences.
2 Findings from the HUPO Plasma
Proteome Project
2.1 MS/MS results
In all, 55 laboratories around the world requested the HUPO
PPP reference specimens of serum and plasma from Cauca-
sian-American, African-American, Asian-American, Chi-
nese, and UK populations [4]. Eighteen of the participating
laboratories conducted a wide range of depletion and frac-
tionation protocols combined with MS/MS or FTICR-MS.
They submitted 42 306 protein identifications using various
search engines and databases to handle spectra and generate
peptide sequence lists from the specimens analyzed. Pep-
tides with .6 amino acids matched to 15 519 non-redundant
proteins in the International Protein Index (IPI) of the Eu-
ropean Bioinformatics Institute in Hinxton, UK [6]. IPI ver-
sion 2.21 (July 2003) was the standard reference database for
this Project. We designed an integration algorithm that
selected one representative protein among multiple proteins
(homologs and isoforms) to which the identified peptides
gave 100% sequence matches [7]. This integration process
resulted in 9504 proteins in the IPI v2.21 database. The PPP
database counts homologous proteins and all isoforms of
particular proteins just once, unless the sequences actually
differentiated additional matches. We have reported details
of the depletion, fractionation, and analytical methods and
the cut-points or filters used by each investigator with the
various search engines linked to different MS/MS instru-
ments [4]. No equivalency rules were applied across all the
search algorithms for all the cut-points. However, Kapp et al.
[8] provided such a cross-algorithm analysis for three speci-
fied false-positive rates using one laboratory dataset and five
search algorithms.
Data management for this Project comprised guidance
and protocols for data collection, centralized integration and
analysis, and dissemination of findings worldwide. Key
challenges were integration of heterogeneous datasets,
reduction of redundant information, dataset annotation,
and how to keep straight progressive submissions and revi-
sions of datasets from a laboratory analyzing multiple
reference specimens with various combinations of technol-
ogy platforms or successive thresholds for the search
engine. Multiple factors had to be balanced, including when
to “freeze” on a particular release of the ever-changing
database selected for the PPP. Freezing of the database was
essential for conducting extensive comparisons of complex
datasets and annotations of the dataset as a whole. However,
it complicates the work of linking findings of the current
study to evolving knowledge of the human genome and its
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annotation. Many of the entries in the IPI protein sequence
database version available at the initiation of the Project
were revised, replaced, or withdrawn over the course of the
Project. This fact complicates all cross-study comparisons;
careful attention to the version of each database used and
interpolation to a common version are essential for such
comparisons. Our policies and practices anticipated the
guidelines issued recently by Carr et al. [9], as documented
by Adamski et al. [7].
Since the approaches and analytical instruments used by
the various laboratories were too diverse to utilize a single
standardized set of mass spec/search engine criteria, we
created a defined subset of protein IDs from the 9504 above
by requiring that the same protein be identified with at least
a second peptide. Since the identification of peptide frag-
ment ions is a low-percentage sampling process, additional
analyses in the same lab and in other labs were expected to
enhance the yield of peptide IDs. As demonstrated by lab 34,
use of an LTQ instrument identified numerous proteins with
two or more peptides that had been identified using an LCQ
instrument with only one (high-confidence) peptide [10].
Consequently, MS data from individual laboratories were
combined to increase the probability of peptide identification
and protein assignment. Many labs reported results with a
variety of methods for depletion of abundant proteins; one
revealing study found new spots on 2-D gels after top-6
depletion, but few new proteins. The new spots were pri-
marily additional isoforms of already-identified moderately
abundant proteins [11].
Of the 9504 protein IDs, 3020 were based on two or
more peptides. The list of 3020 proteins (5102 before inte-
gration) has been utilized as the Core Protein Dataset for
the HUPO PPP knowledge base. Full details with unique
IPI accession numbers for each protein are accessible for
examination and new analyses at the University of Michi-
gan (www.bioinformatics.med.umich.edu/hupo/ppp), Eu-
ropean Bioinformatics Institute (www.ebi.ac.uk/pride),
Institute for Systems Biology (www.peptideatlas.org),
www.TheGPMdb.org, and www.hprd.org Human Pro-
teinpedia websites. As a sample of use [12], during the pe-
riod 5 to 31 January 2005, there were 5000 hits and 1000
downloads of PPP data from PRIDE. The 3020 proteins
represent a very broad sampling of the IPI proteins in terms
of characterization by pI and by molecular weight (MW) of
the transcription product (often a “precursor” protein). The
publicly available PPP database permits future users to
choose their own cut-points for subanalyses, by minimal
number of peptides matching, by confidence criteria, and
especially by re-analysis from the raw spectra. Beer et al. [13]
independently identified 2895 proteins with two or more
peptides using PepMiner and Sequest for major PPP data-
sets, and Beavis matched 5816 IPI proteins with two or
more peptides using X!Tandem [4]. They had 865 and 913
proteins in common with the PPP-3020, respectively. Kapp
[8] and Deutsch [14] used Digger and ProteinProphet/Pep-
tideAtlas on smaller PPP datasets [4].
2.2 Subproteomes
Two laboratories reported glycoprotein enrichment, one with
hydrazide chemistry and the other with binding to three lec-
tins [15, 16]. Together they had 254 protein IDs, of which 164
were reported also by other laboratories, while 90 were iden-
tified only after glycoprotein enrichment. These glycoprotein
findings lay a foundation for the expected very large expan-
sion of glycoprotein analyses with the N-glycosite peptide
resource under preparation by the Aebersold laboratory [17].
Glycoprotein findings can be enhanced also with attention to
the glycans [18, 19].
2.3 Direct MS/SELDI analyses
Ten laboratories requested PPP specimens for analyses with
the then-popular SELDI chip fractionation, MS analysis, and
algorithm-based differentiation of m/z peaks across speci-
mens. Rai et al. [20] reported the cross-laboratory evaluation
of eight submitted datasets, of which five were considered
appropriate for comparison of plasma results and four for
serum results. Correlations across labs were 0.7 or higher for
37 of 42 spectra with S/N.5. More detailed analyses identi-
fied just one protein, haptoglobin, with variation in intensity
of its subunits in different reference specimens. Enhance-
ment of the technology to actually identify proteins was
recommended, along with stringent standardization of pre-
analytical variables, as for all proteomics technology plat-
forms.
2.4 Quantitation of selected proteins
A critical parameter for detection and identification of pro-
teins is the abundance or concentration of the protein and its
isoforms. Haab et al. [21] generated a calibration curve for a
set of sentinel proteins for which quantitative immunoassays
were available. Four different assay methods were performed
for the PPP by DadeBehring, Genomics Institute of Novartis
Foundation, Molecular Staging, and Van Andel Research
Institute. A total of 323 assays measured 237 unique ana-
lytes, although we cannot be certain that different assays for
the presumed same protein targeted the same epitopes. The
results were used to estimate dependence on concentration
for proteins identified by MS. After extensive curation, Haab
et al. matched 76 IPI proteins among the 9504 dataset and 49
proteins among the 3020-protein dataset. The results showed
that the number of peptides identified for a protein in this
collaborative dataset correlates highly with the measured
concentration of the presumed same protein by immuno-
assays (correlation = 0.90 for 76 proteins in the 9504 dataset
and 0.86 for 49 proteins in the 3020 dataset). As expected, the
most abundant proteins are the most readily detected, with
essentially 100% agreement; for much less abundant pro-
teins only the laboratories with protocols and instruments
capable of more sensitive detection identified these proteins.
Biologically interesting proteins with measured concentra-
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tions from 20 ng/mL down to 200 pg/mL include selectin L,
activated leukocyte adhesion molecule, IGFBP-2, TIMP-1,
EGFR, MMP-2/gelatinase, leukemia inhibitory factor recep-
tor, PDGF-R-alpha, TNF-ligand-6, TNF-R-8, and alpha-feto-
protein.
2.5 Annotation of the HUPO PPP Core Dataset
From its inception, the HUPO PPP was designed to facilitate
extensive and innovative annotation of the human plasma
and serum proteome. A large element of the June 2004 Jam-
boree Workshop was collaborative annotation, leading to
several papers in the Proteomics Special Issue [4].
Ping et al. [22] searched for evidence of cleavage of signal
peptides, proteolysis within hydrophobic regions of trans-
membrane sites, and PTMs. Using the 2446 of the 3020
proteins that matched to Ensembl gene products, they high-
lighted subproteomes comprised of glycoproteins, low-MW
proteins and peptides, DNA-binding proteins, and coagula-
tion pathway, cardiovascular, liver, inflammation, and
mononuclear phagocyte proteins. Notable were 216 proteins
matched by Gene Ontology to DNA binding and 350 to the
nucleus, including histone proteins. Liver dominated as the
probable source of proteins, based on Novartis Atlas mRNA
expression profiles for 79 human tissues. Many classic pro-
tein markers of leukocyte, platelet, or macrophage lineages
were not detected, suggesting little contamination of the
plasma. They also highlighted the biological significance of
including semi-tryptic peptides, which might reveal intra-
membrane proteolysis. Berhane et al. [23] focused on 345
proteins of interest for cardiovascular research, classified
into eight categories, most of which relate to other organ
systems, as well: inflammation, vasoactive and coagulation
proteins, signal transduction pathways, growth and differ-
entiation-associated, cytoskeletal, transcription, channels
and receptors, and heart failure and remodeling-related pro-
teins. Muthusamy et al. [24] subjected protein and nucleotide
sequences in NCBI for 2446 genes to BLAST queries, finding
that 51% of the genes encoded more than one protein iso-
form. In addition, they mapped 11 381 single-nucleotide
polymorphisms involving protein-coding regions onto pro-
tein sequences.
With Gene Ontology for subcellular localization, molec-
ular processes, and biological functions, we found a very
broad array of proteins identified. For example, subcellular
classification of the 1276 IPI-3020 proteins included in Gene
Ontology showed 26% from membrane components, 19%
from nuclei, 11% from cytoskeleton, 23% from other cell
types, and just 14% from secreted proteins (“traditional
plasma proteins”). Examination of specific GO terms against
a random sample of 3020 from the human genome [4, 12]
showed over-represented proteins (.3 SD from the expected
line) in categories of extracellular, immune response, blood
coagulation, lipid transport, complement activation, and
regulation of blood pressure, as expected, plus cytoskeletal
proteins, receptors, and transporters. Corresponding Inter-
Pro analyses showed that domains associated with EGF,
intermediate filament protein, sushi, thrombospondin,
complement C1q, and cysteine protease inhibitor were over-
represented (.3 SD) compared with random occurrence,
while zinc finger RING protein, tyrosine protein phospha-
tase, tyrosine and serine/threonine kinases, helix-turn-helix
motif, and IQ calmodulin-binding region were under-repre-
sented. In addition, we noted that 338 of the 3020 IPI pro-
teins matched Ensembl genes in the Online Mendelian
Inheritance in Man database, including such interesting
disease-associated genes as RAG 2 for severe combined
immunodeficiency (SCID/Omenn syndrome), polycystin 1
for polycystic kidney disease, and breast cancer BRCA1 and
BRCA2, multi-cancer p53, and colon cancer APC for inher-
ited cancer syndromes.
Subsequent analyses include reverse protein-to-DNA
matching to identify proteins for previously unidentified
ORF [25] and application of stringent adjustments for pro-
tein length and for multiple comparisons testing [26]. The
latter yielded a data subset of 889 proteins; however, these
particular adjustments may be overly stringent, since they
assume equivalent random matching to all proteins, whereas
proteins occur in various families and have considerable
homologies. The plasma findings have been compared with
those in liver and brain proteomes [27–29], and have helped
to stimulate collective efforts to create protein capture
reagent resources [30] and standard peptide, protein, and
clinical reference specimens [31].
3 How many proteins can be detected in
human plasma and serum?
Counting and comparing numbers of plasma or serum pro-
teins identified is currently a chaotic process, starting with
the biological variables of dynamic range, complexity, and
physiological influences [32]. For any given MS technology
platform, the variables of specimen collection, depletion of
abundant proteins, fractionation of intact proteins, fraction-
ation of tryptic peptides, choice of search engine and detailed
search engine parameters for declaring peptide matches,
choice of protein database and version thereof, consolidation
or integration of multiply matched proteins, risk of false-
positive identifications, and potential loss of true-positive
identifications with stringent criteria to reduce false-positive
identifications lead to extreme differences and awkward
comparisons. The heterogeneity of results across the HUPO
PPP laboratories illustrates the consequences of such varia-
bility of the approach. The inherently incomplete sampling
of any single MS analysis and lack of data on coefficient of
variation for individuals ensure that even a direct replication
of the same specimen in the same lab will have limited con-
cordance (typically ranging from 25 to 50%). Though there
has been a call for up to 5–10 replications per specimen ana-
lyzed [33], present discovery-oriented reports often have no
replication at all.
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Given the exploratory nature of the Pilot Phase, labora-
tories utilized highly variable sets of reference specimens.
In general, those performing extensive depletion and frac-
tionation before tryptic digestion ran few specimens, while
those with shotgun or other high throughput methods ran
multiple reference specimens [4]. This variation limited the
feasibility of cross-comparisons within the collaborative
dataset.
There is a growing literature of results from extensive
analyses of human plasma and serum specimens,
enhanced by the PPP. Here we summarize certain features
of previously published studies and compare the overlap of
protein identifications with the PPP-3020 Core Dataset (see
Table 1 and ref. [12]). The numbers of proteins depend on
many factors, including the extent of fractionation and
number of MS/MS runs with the sample, the number of
peptide ions sequenced in MS/MS, the stringency of cri-
teria for identification of peptides and minimization of
false-positives, the restriction to tryptic or semi-tryptic
peptides, the exclusion or inclusion of immunoglobulins
and keratins, and the tolerance for multiple ambiguous
assignments of the peptides to proteins in gene or protein
databases.
3.1 Published analyses from others
Anderson et al. [34] published a compilation of 1175 non-
redundant proteins reported in at least one of four sources
(a literature review plus three experimental datasets). Of the
1175, only 195 were reported in any two of the four input
datasets; only 46 proteins were reported in all four sources;
284 of the 468 reported in the non-proteomic literature were
not found in any of the three experimental datasets; and
only three of the 46 were not already known in the litera-
ture. Patterson and colleagues [35] suggested that such dis-
cordance reflects high false-positive rates from reliance on
single-peptide hits. Shen et al. [36] used high-efficiency
nanoscale RP-LC and strong cation exchange LC in con-
junction with IT-MS/MS, Sequest peptide identification cri-
teria (with and without chymotryptic and elastic peptides),
and peptide LC normalized elution time constraints. Be-
tween 800 and 1682 human proteins were identified,
depending on the criteria. They did not deplete albumin or
immunoglobulins. Chan et al. [37] resolved and analyzed
tryptic peptides from a Sigma pooled standard serum into
20 fractions by ampholyte-free liquid phase IEF, followed by
strong cation-exchange chromatography, generating 7620
fractions, which were analyzed by microcapillary RP-LC-
MS/MS with an LCQ-DecaXP. In summary, they identified
1444 unique proteins from 2646 unique peptides after
searching with Sequest against the Expert Protein Analysis
System (www.expasy.org) database. A high percentage of
proteins were based on just a single peptide (http://
bpp.nci.nih.gov). Zhou et al. [38] identified an aggregate of
210 low-MW proteins or peptides after multiple immuno-
precipitation steps with antibodies against albumin, IgA,
IgG, IgM, transferrin, and apolipoprotein, followed by RP-
LC-MS/MS. This aggregate result comprises 9 different
experimental methods. Of these proteins, 73 and 67% were
not found by the same lab in previous studies of the low-
MW or whole-serum proteome [37]. There was no duplicate
analysis to ascertain the concordance with the same meth-
od, same sample, and same lab. A grand total of only 378
unique peptides (not limited to tryptic peptides) was identi-
fied, which matched to 210 proteins; only 1 was identified
by Adkins et al. [39] in serum depleted of IgG then analyzed
by LC-MS/MS, only 4 in plasma by 2-DE with MS, and only
70 of the 1500 claimed by Chan et al. [37]. Rose et al. [40]
reported an industrial-scale fractionation, starting with 6 L
of blood/2.5 L of plasma from 53 healthy males, depleted of
albumin and IgG with affinity resin and protein G, respec-
tively, to yield 53 g total protein. Proteins of MW , ca
40 kDa, 1.5 g after gel filtration, were separated into 12 960
chromatographic fractions. Fragments of larger proteins
could not be excluded. ESI-MS and MALDI-TOF-MS were
performed on the small proteins on MALDI plates, then
aliquots of tryptic digests were subjected to LC-ESI-MS/MS;
1.5 million MS/MS spectra were analyzed with six different
databases to yield 405 different proteins, of which 115 were
based on a single peptide. When their criteria were applied
to the Adkins et al. list of 490 proteins [39], only 164 of the
more common proteins were retained.
Table 1. Overlap of HUPO PPP protein identifications with pub-











Anderson [34] 1175 990 471 316
Shen [36] 1682 1842 526 213
Chan [37] 1444 1019 402 257
Zhou [38] 210 148 88 62
Rose [40] 405 287 159 142
3.2 Degree of overlap of HUPO PPP protein ID with
published studies of the plasma or serum
proteome
Table 1 presents the matches of the five published studies
described above with the HUPO PPP protein identifica-
tions. Of the 990 proteins which have IPI v2.21 identifiers
in the four studies compiled by Anderson et al. [34], 316 are
found in the PPP 3020 protein Core Dataset. When we
relaxed the integration requirement (5102 IPI IDs), this
figure rose only to 356 matches. Using the full 9504 dataset,
the corresponding matches were 471 with integration and
539 without integration. We re-ran the raw spectra of Shen
et al. [36] using HUPO PPP Sequest parameters and
obtained 1842 IPI protein matches. Of these, 526 and 213
were found in the PPP 9504 and 3020 datasets, respectively.
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When we mapped the 1444 proteins reported by Chan et al.
[37] against the IPI v2.21 database, there were 1019 distinct
proteins. From this set, 402 and 257 proteins matched with
the 9504 and 3020 datasets, respectively. With the Zhou et
al. [38] protein-bound proteins, 148 proteins were mapped
with IPI identifiers, of which 88 and 62 were found in the
9504 and 3020 PPP protein lists, respectively. Finally, of the
287 low-MW proteins (,40 kDa) from Rose et al. [40] which
mapped to IPI v2.21identifiers, 159 and 142 are included in
our 9504 and 3020 protein datasets, respectively.
These datasets vary remarkably in the protocols for
depletion and/or fractionation, the criteria for protein ID,
and the inclusion or depletion of immunoglobulins. All
claim some relatively low abundance proteins. Never-
theless, abundance remains the single strongest determi-
nant of protein detectability by mass spectrometry, and
nearly all of the proteins detected in common across mul-
tiple studies are present at relatively high concentrations in
blood.
Error rate estimation is a nascent aspect of the literature
and a major source of lack of concordance. Methods include
use of statistical criteria, as in PeptideProphet/ProteinPro-
phet [41]; matching to non-human protein sequence data-
bases (Archea); matching to reversed sequence [37] or shuf-
fled sequence human databases; Poisson distribution meth-
ods [7]; or modeling of random matches to length of protein
sequences [26]. The closest to standard usage is the Trans-
Proteomic Pipeline based on PeptideProphet/ProteinPro-
phet.
4 Plasma vs. serum as the sample of
choice
Pre-analytical variables are often ignored or reported
casually in the proteomic analysis and comparison of
samples. These variables will be critically important in
disease marker research. When blood is collected, many
changes in proteins occur due to proteolytic enzymes
(proteases) and other enzymes that are active in the blood
sample during handling and processing. At the HUPO
Jamboree concerns were raised that proteins from blood’s
cellular components may be released ex vivo due to hemo-
lysis (breakdown of red blood cells with release of hemo-
globin and other proteins), platelet activation (enhanced at
47C, at least in some individuals, with release of platelet
basic protein, thymosin-beta-4, platelet factor 4, zyxin as
platelet markers), or white blood cell degranulation or
breakdown with release of proteins. All of these proteins,
especially the platelet markers, were found only with low
numbers of peptides, signifying low concentration, in the
PPP reference specimens.
Plasma is converted to serum by permitting or activating
clot formation, usually at room temperature, which involves
the protease action of thrombin on fibrinogen and related
protein targets and other proteases on other proteins of the
coagulation cascade. The forming clot itself provides a phys-
ical scaffold for attachment of proteins. Plasma can be pro-
tected from clotting by use of sodium citrate, K2-EDTA, or
lithium heparin as anti-coagulant.
The HUPO PPP Specimens Committee [42] and the
collaborating investigators [4] concluded that EDTA-plasma
should be recommended as the preferred specimen from
blood. This recommendation was endorsed at the HUPO 5th
World Congress of Proteomics in Long Beach, CA, Oct
2006. Although truly systematic studies of the numerous
variables involved are not available, scientists from several
companies also supported this recommendation, based on
unpublished experience. The reasons are (i) less degrada-
tion ex vivo and (ii) much less variability than arises in the
protease-rich process of clotting. In the PPP, Misek et al.
[43] showed with Cy5, Cy3, Cy2-labeled serum and plasma
on DIGE-2D-PAGE after extensive fractionation of intact
proteins before tryptic digestion that isoforms of abundant
proteins were shifted to lower-than-expected MW more in
serum than in plasma, and Tammen et al. from BioVisioN
[44] reported that 40% of the low-MW peptides detected
were serum specific. Clotting is unpredictable, due to
influences of temperature, time, and medications, which
are hard to standardize. Among anti-coagulants, heparin is
a polyanion that activates anti-thrombin III; it may interfere
in MS. Both citrate and EDTA inhibit coagulation and other
enzymatic processes by chelate formation with ion-depend-
ent enzymes. Citrate, however, introduces a 10–15% dilu-
tion effect, since it alone is added in solution. The PPP
investigators therefore recommend EDTA-plasma as the
preferred specimen from blood.
At present, we have left open the question of whether to
include protease inhibitors in the collection tubes or buffers.
Among the usual components of these cocktails, the peptide
inhibitor aprotinin requires mg/mL concentrations, which
may interfere with the analyses, while the small molecule
inhibitor ABESF forms covalent bonds with proteins that
alter the mobility of the protein [42]. BD has proposed that
the PPP also use their new P100 EDTA-plasma tube, with a
proprietary protease inhibitor cocktail and a mechanical
separator of cells, which has been reported at HUPO and
ASMS meetings to give more consistent results (Craft, D., Yi,
J., Gelfand, C. A., An in-depth look at plasma peptidome
stability in different blood collection tubes using LC-MALDI-
MS. ASMS 2006, poster 578). Protocols for the standard
EDTA-plasma and for the P100 tube have been prepared for
the PPP next phase.
Meanwhile, a surprising finding that disease-related pat-
terns of ex vivo proteolysis in plasma undergoing clotting to
form serum may be clinically useful has been reported by the
Tempst laboratory [45]. There are striking differences in
peptide patterns between sera from bladder, breast, and
prostate cancer patients compared with normals or with the
other groups of cancer patients, presumably due to amino or
carboxy peptidases. Protease inhibitors are not used in such
experiments.
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5 Comparisons of overlap of plasma
proteome with proteomes of other
biofluids
Reference specimen-quality results have been published
from the laboratory of Matthias Mann for urine [46], tear
fluid [47], and seminal fluid [48] using the potent new tech-
nologies platforms of hybrid linear IT-Fourier transform
(LTQ-FT) and linear IT-Orbitrap (LTQ-Orbitrap) after frac-
tionation of the intact proteins. Overlap with the HUPO
PPP-3020 proteins is shown in Table 2. Of the 1543 proteins
identified in urine, 910 were in the IPI v2.21 database, of
which 293 were identified in the HUPO PPP-3020. The cor-
responding numbers for tears and semen are given in
Table 2. We are also collaborating in a study of salivary fluid
(Yan, W., Yu, W., Mueller, M., Cole, S. et al., Systematic com-
parison of two human body fluid proteomes: saliva and
plasma. Abst, HUPO 5th World Congress, Long Beach, CA,
Oct 31, 2006), in which 1134 protein clusters were found, of
which 432 are in the PPP-3020 database. Yamamoto et al. [49]
have identified 3680 proteins from 2 or more peptides in
urine in the HUPO Human Kidney-Urine Proteome Project.
Meanwhile, Beretta reported at the January 2007 HUPO
Initiatives Workshop over 8000 protein IDs after LTQ analy-
sis of 193 protein fractions, of which 792 matched to the
PPP-3020. Other studies of biofluid and organ proteomes
being reported in this Issue will be interesting to compare for
overlap with the plasma proteome.
This work will be enhanced by the HUPO/Invitrogen
Test Sample Project announced in 2006 to assess MS cap-
abilities of participating laboratories for sensitivity of detec-
tion, accuracy of identification, relative quantitation, and
recognition of false-positive identifications. The first test
sample has a carefully designed mixture of 20 highly purified
human proteins produced in Escherichia coli. The proteins
will be unknowns for the labs. The 20 proteins have equi-
molar concentrations (5 pmoles in 50 mL) and represent a
wide range of pI, MW, and hydrophobicity. All labs, both
academic and corporate, are encouraged to participate, to
improve performance throughout the proteomics commu-
nity. Subsequent protein mixtures are planned with widely
varying concentrations and then larger numbers of proteins
(greater complexity).
The National Cancer Institute, the National Institute for
Standards and Technology, the European Bioinformatics
Institute, and various academic and industry scientists have
shown high interest in standardized reference materials of
Table 2. Overlap of new biofluid proteome findings with HUPO
PPP-3020 protein list
Proteome Proteins IPI 2.21 PPP-3020 Ref.
Urine 1543 910 293 [46]
Tears 491 313 117 [47]
Semen 923 560 180 [48]
peptides, protein mixtures, and biological specimens [31].
Examples of standard mixtures include the CRM 470 of 15
human plasma proteins, widely used in Europe; the 18 non-
human commercial proteins combined into a standard mix-
ture by Keller et al. [50] at the Institute for Systems Biology;
and tryptic digests of 300 commercially available proteins,
for each of which at least 25 spectra have been generated with
MALDI-TOF/TOF for use as standards in calibrating instru-
ments and spiking samples (Strahler, J. R., Veine, D., Walker,
A., Ulintz, P. et al., A publicly available dataset of MALDI-
TOF/TOF and LTQ mass spectra of known proteins. ASMS
2005, Bioinformatics poster 398).
The HUPO Protein Standards Initiative has generated
several consensus standards [29, 51], including publications
pending in Nature Biotechnology (2007) on Molecular Inter-
actions, Sample Processing (MIAPE), Gel Electrophoresis,
Mass Spectrometry (merging mzDATA and mzXML), Pro-
tein Modifications, and Proteomics Informatics and Con-
trolled Vocabularies (www.psidev.info).
6 Concept for the next phase of the human
Plasma Proteome Project
Present plans for the next phase of the PPP, co-chaired by
Ruedi Aebersold, Young-Ki Paik and Gil Omenn, include the
following elements: (i) voluntary participation and real-time
contribution of large datasets from major laboratories using
advanced technology platforms, analyzing plasma and/or
serum, often in combination with organ or disease proteome
studies; (ii) standard specimen collection, using EDTA-
plasma protocols; and (iii) a robust informatics effort with
collaborative cross-analyses of plasma findings from multi-
ple HUPO initiatives and from other published work.
The Holy Grail for plasma proteomics is high-resolution,
high-sensitivity, and high-throughput analysis. It is certain
that most of the protein biomarkers of greatest interest ori-
ginating from disease processes in specific tissues will be at
quite low abundance after dilution into 4L of blood and 17L
of extracellular fluid. Thus, targeted approaches linked to
proteomics findings of disease relevance in sites of primary
disease and proximal biofluids are logical strategies [52]. In
order to perform proteomics analyses on dozens, hundreds,
or thousands of specimens from participants in clinical trials
or epidemiological studies, and do so with replicates to
assess intra-individual variation, new strategies with high
throughput must complement the presently laborious
methods for discovery and even validation of potential pro-
tein biomarkers.
Fortunately, new technology platforms for global analysis
using LTQ-FT, LC-MS/MS/MS, and LTQ-Orbitrap [53, 54]
and new platforms for targeted proteomics using heavy-iso-
tope-labeled N-glycosite-containing proteotypic peptides [17,
55] and/or multiple reaction monitoring (MRM) with or
without anti-peptide antibodies [56] offer great promise. Ad-
ditional mining of high-quality spectra may increase yields of
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protein identifications, as well [57]. High-accuracy LC-MS/
MS/MS has been applied to intracellular localization and
discovery-phase identification of PTMs [54]. As it is likely
that most differences between specimens from patients with
disease versus specimens from normals may be quantitative,
methods of quantitative proteomics, such as isotope-coded
affinity tags (ICAT), iTRAQ, and DIGE may be essential.
Aebersold is developing a resource that will offer chemically
synthesized NxS/T peptides tagged with heavy isotope for
each gene and eventually each protein isoform needed for
high discrimination as biomarkers [55]. These “proteotypic
peptides” would permit spiking of specimens to facilitate
identification of mass pairs with the same peptides in the
biological specimen and quantitation of the peptide and its
protein [17]. A multiplexed multiple reaction monitoring
(MRM) approach with 1-D LC-MS/MS can be exploited to
identify and quantitate high and medium abundance pro-
teins which may have value as biomarkers. This approach
has many potential variations, including use of sensitive
anti-peptide antibody-enhanced assays for lower-abundance
proteins [56]. These methods will be at the heart of the new
phase of the HUPO PPP. Plasma analyses will be the final
common pathway as investigators link studies of organ pro-
teomes and disease biomarker discovery in biofluids with
findings in plasma specimens collected under standardized
conditions from the same patients at the same time.
7 Pitfalls in biomarker discovery and
validation studies
Since the next phase of the PPP will be coupled with the
umbrella HUPO Biomarker Initiative [3], a few comments
on such studies are in order. Ransohoff [58, 59] outlined
many sources of bias that may invalidate biomarker studies,
regardless of technology platform. Bias occurs when cancer
and non-cancer groups or their specimens are handled in
systematically different ways, which occurs often. Problems
arise in study design, selection of individuals, collection and
processing of specimens, and complicated gene expression
and proteomic laboratory analyses. Randomized clinical
trials are designed to provide a fair and unbiased comparison
by the creation of duplicate sets of circumstances in which
only one factor that is relevant to the outcome is permitted to
vary; other sources of variation can be evaluated against the
independent variable. This principle of “keeping all variables
equal between groups” is difficult to achieve in observational
studies. Bias is more difficult to address in study design,
conduct, and interpretation than such other problems as the
generalizability of results and the influence of “chance”. Bias
is unconscious and unintentional. For example, if samples
from elderly hospitalized cancer patients are compared with
samples from young lab workers, any variables associated
with age or hospitalization could dominate the differences
found. Similarly, specimens collected at different times by
different staff or in different locations, are likely to carry
critical differences unrelated to the disease under study. If
cancer patient specimens have been stored for many years
longer than non-cancer control individuals’ specimens, une-
valuated variables may accumulate. In better designs, indi-
viduals are selected for sampling and study before they
receive the test that is being assessed and before it is known
whether they have the disease, as in prospective population
studies. Every participant would receive the same evaluation
for the test and the disease and, hopefully, have specimen
collection under identical protocols in the same laboratories.
Regrettably, the amount of detail on such variables typi-
cally provided in publications is meager to perfunctory, whe-
ther one depends upon the published text or the supple-
mentary material. Detailed guidelines have been published
for Minimum Information about Microarray Experiments
(MIAME) and Minimum Information about Proteomics
Experiments (MIAPE) (www.psidev.info), and for research
publications [60]. A multi-author paper with guidance for
clinical proteomics has appeared in this Journal [61], giving
attention to selection of donors of specimens, detailed diag-
nostic criteria, and preanalytical aspects, including specimen
collection and handling. A scheme called Standards for
Reporting of Diagnostic Accuracy (STARD) [62] guides
investigators and readers to sources of bias and details to be
considered and be prevented. It is crucial to recognize that
certain important aspects of study design do not overcome
bias: (i) large sample size, which reduces the statistical con-
fidence interval around a result; (ii) reproducibility of find-
ings, as in use of training and testing sets of samples; and
(iii) sophisticated statistical analyses of collected data. None
of these methods and no guidelines for reporting can replace
the investigator’s insight and careful attention to details in
seeking to ensure equality of characteristics of individuals
studied, specimen collection, handling, and storage, and
time and place of analyses.
8 Concluding remarks
Biomarker discovery is now a main theme in each of the
many HUPO initiatives. There is increased awareness of the
challenges ahead of us in biomarker discovery. In particular,
the need for cross-laboratory examination of datasets from
various organs, careful validation of targets, and establish-
ment of regularly updated databases, is better appreciated.
The path toward collaborative biomarker discovery at HUPO
was initiated with the HPPP, and the work on plasma pro-
teome functional annotation has inspired and facilitated
many follow-up analyses. Organ-specific cross-analyses be-
tween the HPPP and the Liver and Brain Proteome Projects
are being conducted, and cross-analyses of the Kidney-Urine,
Salivary, and other projects will be organized.
In summary, work on all aspects of proteomics has gen-
erated renewed confidence that such approaches will reveal
important features of normal biology and physiology and
assist in the discovery, validation, and application of protein
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biomarker panels in early diagnosis of disease and monitor-
ing responses to therapies. Overall, the technical advances of
proteomics and the intellectual power of international and
inter-sectoral collaboration place HUPO in a key position to
lay a strong foundation for clinical proteomics, through
credible application of protein biomarkers in population
screening and eventually in patient care.
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